Recent advances on vaccines against malaria: A review

Abstract

This review aims to summarize the currently viable vaccine strategies including the approved vaccines and the those in trials for next-generation malaria vaccines. Data on malaria vaccine development was collected through a comprehensive review. The literature search was performed using databases including Google Scholar, PubMed, NIH, and Web of Science. Various novel approaches of vaccination are being developed, including those based on radiation-attenuated strategies, monoclonal antibodies, targeted immunogenic peptides, RNA and DNA vaccines, nanoparticle-based vaccines, protein-based vaccination protocols, and whole organism-based vaccination strategies. Trials on RTS, S have entered phase III testing, and those based on blood-stage vaccines and vaccines to interrupt malarial transmission have advanced to higher stages of trials. Mathematical modeling, combined drug and vaccine strategies, mass drug administration, polyvalent vaccine formulations, and targeted vaccination campaigns is playing an important role in malarial prevention. Furthermore, assessing coverage, accessibility, acceptability, deployment, compilation, and adherence to specific vaccination strategies in endemic regions is essential for vaccination drives against malaria.

Keywords

Vaccines against malaria / Drugs and adjuvant / Malarial treatment / RTS / S vaccine

References

[1] Brejt JA, Golightly LM. Severe malaria: Update on pathophysiology and treatment. Curr Opin Infect Dis 2019; 32: 413-418. doi: 10.1097/qco.0000000000000584.

[2] Patel P, Faladia M, Shah P, Patel J. Nanotechnology based vaccination approach in malarial infection. In: Shegokar R, Pathak Y, eds. Infectious diseases drug delivery systems. Switzerland: Springer; 2023, p. 127-145.

[3] Figueroa-Romero A, Pons-Duran C, Gonzalez R. Drugs for intermittent preventive treatment of malaria in pregnancy: Current knowledge and way forward. Trop Med Infect Dis 2022; 7: 152. doi: 10.3390/tropicalmed7080152.

[4] Mascola JR, Fauci AS. Novel vaccine technologies for the 21st century. Nat Rev Immunol 2019; 20: 87-88. doi: 10.1038/s41577-019-0243-3.

[5] Nadeem AY, Shehzad A, Islam SU, Al-Suhaimi EA, Lee YS. MosquirixTM RTS, S/AS01 vaccine development, immunogenicity, and efficacy. Vaccines 2022; 10: 713. doi: 10.3390/vaccines10013.

[6] Moon JE, Ockenhouse C, Regules JA, Vekemans JL, Chuang C, Traskine MI, et al. A phase II a controlled human malaria infection and immunogenicity study of RTS, S/AS01E and RTS, S/AS01B delayed fractional dose regimens in malaria-naive adults. J Infect Dis 2020; 222: 1681-1691. doi: 10.1093/infdis/jiaa421.

[7] Arora N, Anbalagan LC, Pannu AK. Towards eradication of malaria: Is the WHO’s RTS, S/AS01 vaccination effective enough? Risk Manag Health Policy 2021; 14: 1033-1039. doi: 10.2147/rmhp.s219294.

[8] Arora M, Lakshmi RV. Vaccines-safety in pregnancy. Best Pract Res Clin Obstet Gynaecol 2021; 76: 23-40. doi: 10.1016/j.bpobgyn.2021.02.002.

[9] Briggs J, Ategeka J, Kajubi R, Ochieng T, Kakuru A, Ssemanda C, et al. Impact of microscopic and submicroscopic parasitemia during pregnancy on placental malaria in a high-transmission setting in Uganda. J Infect Dis 2019; 220: 457-466. doi: 10.1093/infdis/jiz130.

[10] Sinnis P, Fidock DA. The RTS, S vaccine-a chance to regain the upper hand against malaria? Cell 2022; 185: 750-754. doi: 10.1016/j.cell.2022.01.028.

[11] Moorthy V, Binka F. R21/Matrix-M: A second malaria vaccine? Lancet 2021; 397: 1782-1783. doi: 10.1016/s0140-6736(21)01065-5.

[12] Pollard AJ, Bijker EM. A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol 2020; 21: 83-100. doi: 10.1038/s41577-020-00479-7.

[13] Lee WC, Cheong FW, Amir A, Lai MY, Tan JH, Phang WK, et al. Plasmodium knowlesi: The game changer for malaria eradication. Malar J 2023; doi: 10.1186/s12936-023-04732-x.

[14] Choutos D, Poulaki A, Piperaki ET. Malaria in children: Updates on management and prevention. Pediat Infect Dis J 2023; 42: e116-e118. doi: 10.1097/inf.0000000000003746.

[15] Borkens Y. Malaria & mRNA vaccines: A possible salvation from one of the most relevant infectious diseases of the global south. Acta Parasitol 2023; doi: 10.1007/s11686-023-00712-y.

[16] González-Sanz M, Berzosa P, Norman FF. Updates on malaria epidemiology and prevention strategies. Curr Infect Dis Rep 2023; 25: 131-139. doi: 10.1007/s11908-023-00805-9.

[17] Rosenthal PJ, John CC, Rabinovich NR. Malaria: How are we doing and how can we do better? Am J Trop Med Hyg 2019; 100: 239-241. doi: 10.4269/ajtmh.18-0997.

[18] Marques-da-Silva C, Peissig K, Kurup SP. Pre-erythrocytic vaccines against malaria. Vaccines 2020; 8: 400. doi: 10.3390/vaccines8030400.

[19] Moser KA, Drábek EF, Dwivedi A, Stucke EM, Crabtree J, Dara A, et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genom Med 2020; doi: 10.1186/s13073-019-0708-9.

[20] Torres KJ, Castrillon CE, Moss EL, Saito M, Tenorio R, Molina DM, et al. Genome-level determination of Plasmodium falciparum blood-stage targets of malarial clinical immunity in the Peruvian Amazon. J Infect Dis 2014; 211: 1342-1351. doi: 10.1093/infdis/jiu614.

[21] Tumwine-Downey I, Deroost K, Levy P, McLaughlin S, Hosking C, Langhorne J. Antibody-dependent immune responses elicited by blood stage-malaria infection contribute to protective immunity to the pre-erythrocytic stages. Curr Res Immunol 2023; 4: 100054. doi: 10.1016/j.crimmu.2022.100054.

[22] Doritchamou JYA, Suurbaar J, Tuikue Ndam N. Progress and new horizons toward a VAR2CSA-based placental malaria vaccine. Expert Rev Vacc 2021; 20: 215-226. doi: 10.1080/14760584.2021.1878029.

[23] Gheibi HSM, Darroudi M. Nanovaccine: A novel approach in immunization. J Cell Physiol 2019; 234: 12530-12536. doi: 10.1002/jcp.28120.

[24] Cooper MM, Loiseau C, McCarthy JS, Doolan DL. Human challenge models: Tools to accelerate the development of malaria vaccines. Expert Rev Vacc 2019; 18: 241-251. doi: 10.1080/14760584.2019.1580577.

[25] Duffy PE. Current approaches to malaria vaccines. Curr Opin Microbiol 2022; 70: 102227. doi: 10.1016/j.mib.2022.102227.

[26] Opi DH, Kurtovic L, Chan JA, Horton JL, Feng G, Beeson JG. Multi-functional antibody profiling for malaria vaccine development and evaluation. Expert Rev Vacc 2021; 20: 1257-1272. doi: 10.1080/14760584.2021.1981864.

[27] Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: Progress, priorities, products. NPJ Vacc 2020; doi: 10.1038/s41541-020-0196-3.

[28] Naung MT, Martin E, Munro J, Mehra S, Guy AJ, Laman M, et al. Global diversity and balancing selection of 23 leading Plasmodium falciparum candidate vaccine antigens. PLoS Comp Biol 2022; 18: e1009801. doi: 10.1371/journal.pcbi.1009801.

[29] Laurens MB. Novel malaria vaccines. Hum Vaccin Immunother 2021; 17: 4549-4552. doi: 10.1080/21645515.2021.1947762.

[30] Duffy PE. Making a good malaria vaccine better. Trends Parasitol 2022; 38: 9-10. doi: 10.1016/j.pt.2021.11.

[31] da Mariano RMS, Gonçalves AAM, Oliveira DS, de Ribeiro HS, Pereira DFS, Santos IS, et al. A review of major patents on potential malaria vaccine targets. Pathogens 2023; 12: 247. doi: 10.3390/pathogens12020247.

[32] Miyazaki Y, Marin-Mogollon C, Imai T, Mendes AM, van der Laak R, Sturm A, et al. Generation of a genetically modified chimeric Plasmodium falciparum parasite expressing Plasmodium vivax circumsporozoite protein for malaria vaccine development. Front Cell Infect Microbiol 2020; doi: 10.3389/fcimb.2020.591046.

[33] Frontiers Editorial Office. Expression of concern: A multi-stage Plasmodium vivax malaria vaccine candidate able to induce long-lived antibody responses against blood stage parasites and robust transmission-blocking activity. Front Cell Infect Microbiol 2023; 13: 1292315. doi: 10.3389/fcimb.2023.1292315.

[34] Lundstrom K. Self-amplifying RNA viruses as RNA vaccines. Int J Mol Sci 2020; 21: 5130. doi: 10.3390/ijms21145130.

[35] Fotoran WL, Silva JR, da Glitz C, Ferreira LC, de Wunderlich GS. Establishment of an antiplasmodial vaccine based on PfRH5-encoding RNA replicons stabilized by cationic liposomes. Pharmaceutics 2023; 15: 1223. doi: 10.3390/pharmaceutics15041223.

[36] Nureye D, Assefa S. Old and recent advances in life cycle, pathogenesis, diagnosis, prevention, and treatment of malaria including perspectives in Ethiopia. Sci Worl J 2020; 2020: 1-17. doi: 10.1155/2020/1295381.

[37] Belete TM. Recent progress in the development of new antiepileptic drugs with novel targets. Ann Neurosci 2023; 30(4): 262-276. doi: 10.1177/09727531231185991.

[38] Yan der Pluijm RW, Amaratunga C, Dhorda M, Dondorp AM. Triple artemisinin-based combination therapies for malaria-a new paradigm? Trends Parasitoll 2021; 37: 15-24. doi: 10.1016/j.pt.2020.09.011.

[39] Nordmann T, Borrmann S, Ramharter M. Drug-induced hypersensitivity to artemisinin-based therapies for malaria. Trends Parasit 2022; 38: 136-146. doi: 10.1016/j.pt.2021.08.011.

[40] Rosenthal PJ. Are artemisinin-based combination therapies for malaria beginning to fail in Africa? Am J Trop Med Hyg 2021; 105: 857-858. doi: 10.4269/ajtmh.21-0797.

[41] Chatterjee D, Cockburn IA. The challenges of a circumsporozoite protein-based malaria vaccine. Expert Rev Vacc 2021; 20: 113-125. doi: 10.1080/14760584.2021.1874924.

[42] Tindana P, de Haan F, Amaratunga C, Dhorda M, Van Der Pluijm RW, Dondorp AM, et al. Deploying triple artemisinin-based combination therapy (TACT) for malaria treatment in Africa: Ethical and practical considerations. Malar J 2021; 20(1): 119. doi: 10.1186/s12936-021-03649-7.

[43] Dickey TH, Tolia NH. Designing an effective malaria vaccine targeting Plasmodium vivax Duffy-binding protein. Trends Parasitol 2023; 39: 850-858. doi: 10.1016/j.pt.2023.06.011.

[44] Schneider CG, Taylor JA, Sibilo MQ, Miura K, Mallory KL, Mann C, et al. Orientation of antigen display on self-assembling protein nanoparticles influences immunogenicity. Vaccines 2021; 9: 103. doi: 10.3390/vaccines9020103.

[45] Matarazzo L, Bettencourt PJG. mRNA vaccines: A new opportunity for malaria, tuberculosis and HIV. Front Immunol 2023; 14: 1172691. doi: 10.3389/fimmu.2023.1172691.

[46] Pendyala G, Calvo-Calle JM, Moreno A, Kane RS. A multivalent Plasmodium falciparum circumsporozoite protein-based nanoparticle malaria vaccine elicits a robust and durable antibody response against the junctional epitope and the major repeats. Bioeng Trans Med 2023; 8(4): e10514. doi: 10.1002/btm2.10514.

[47] Alves KCS, Guimarães JMM, Almeida MEM, De Mariúba LAM. Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: A brief review. Rev Inst Med Trop Sao Paulo 2022; 8(4): e10514. doi: 10.1590/s1678-9946202264023.

[48] Kessy SA, Tibenderana JR. Zanzibar’s malaria elimination efforts: Progress, challenges, and lessons. Lancet 2023; 402: 774. doi: 10.1016/s0140-6736(23)01467-8.

[49] Moita D, Maia TG, Duarte M, Andrade CM, Albuquerque IS, Dwivedi A, et al. A genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against Pvivax malaria. NPJ Vacc 2022; 7(1): 163. doi: 10.1038/s41541-022-00585-8.

[50] Larkin H. Whole-sporozoite malaria vaccine candidate shows real-world promise. JAMA 2023; 329: 115. doi: 10.1001/jama.2022.235.

[51] Van der Boor SC, Alkema M, van Gemert GJ, Teelen K, van de Vegte-Bolmer M, Walk J, et al. Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial. BMC Med 2023; doi: 10.1186/s12916-023-02788-9.

[52] Tripathi H, Bhalerao P, Singh S, Arya H, Alotaibi BS, Rashid S, et al. Malaria therapeutics: Are we close enough? Parasit Vect 2023; 16(1): 130. doi: 10.1186/s13071-023-05755-8.

[53] Etefia E, Etoh PI. Malaria vaccine development: Challenges and prospects. Med Pharma J 2023; 2: 28-42. doi: 10.55940/medphar202225.

[54] Quagliata M, Papini AM, Rovero P. Malaria vaccines. Expt Opini Ther Pat 2023; 33: 169-178. doi: 10.1080/13543776.2023.2190884.

[55] Daubenberger C. Assessment of experimental malaria vaccine induced protection in pre-exposed populations. Lancet Infect Dis 2022; 22: 305-307. doi: 10.1016/s1473-3099(21)00359-5.

[56] Siddiqui AJ, Bhardwaj J, Saxena J, Jahan S, Snoussi M, Bardakci F, et al. A critical review on human malaria and schistosomiasis vaccines: Current state, recent advancements, and developments. Vaccines 2023; 11: 792. doi: 10.3390/vaccines11040792.

[57] Good MF, Stanisic DI. Biological strategies and political hurdles in developing malaria vaccines. Expt RevVacc 2021; 20: 93-95. doi: 10.1080/14760584.2021.1889094.

[58] McLeod B, Mabrouk MT, Miura K, Ravichandran R, Kephart S, Hailemariam S, et al. Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses. Immunity 2022; 55: 1680-1692.e8. doi: 10.1016/j.immuni.2022.07.015.

[59] Zahedi F, Mehrizi A, Sardari S, Alemzadeh I. Design and development of a self-assembling protein nanoparticle displaying PfHAP2 antigenic determinants recognized by natural acquired antibodies. PLoS One 2022; 17: e0274275. doi: 10.1371/journal.pone.0274275.

[60] Makoni M. mRNA vaccine against malaria effective in preclinical model. Lancet Microb 2023; doi: 10.1016/s2666-5247(23)00332-4.

[61] Nadeem A, Bilal W. Acceptance, availability and feasibility of RTS, S/AS01 malaria vaccine: A review of literature. Asian Pac J Trop Med 2023; 16(4): 162-168.

[62] Yenkoidiok-Douti L, Barillas-Mury C, Jewell CM. Design of dissolvable microneedles for delivery of a Pfs47-based malaria transmission-blocking vaccine. ACS Biomater Sci Eng 2021; 7: 1854-1862. doi: 10.1021/acsbiomaterials.0c01363.

[63] Ghebreyesus TA. The malaria eradication challenge. Lancet 2019; 394: 990-991. doi: 10.1016/s0140-6736(19)31951-8.

[64] Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The role of AI in drug discovery: Challenges, opportunities, and strategies. Pharmaceutics 2023; 16: 891. doi: 10.3390/ph16060891.

[65] Mangou K, Moore AJ, Thiam LG, Ba A, Orfanó A, Desamours I, et al. Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5. Sci Rep 2022; 12(1): 19403. doi: 10.1038/s41598-022-23929-9.

[66] Moormann AM, Nixon CE, Forconi CS. Immune effector mechanisms in malaria: An update focusing on human immunity. Parasit Immunol 2019; 41(8): e12628. doi: 10.1111/pim.28.

[67] Krampa FD, Aniweh Y, Kanyong P, Awandare GA. Recent advances in the development of biosensors for malaria diagnosis. Sensors 2020; 20: 799. doi: 10.3390/s20030799.

[68] Duffy PE. Transmission-blocking vaccines: Harnessing herd immunity for malaria elimination. Expert Rev Vacc 2021; 20(2): 185-198. doi: 10.1080/14760584.2021.1878028.

[69] Heaton PM. Challenges of developing novel vaccines with particular global health importance. Front Immunol 2020; 11: 517290. doi: 10.3389/fimmu.2020.517290.

[70] Funwei R, Nderu D, Nguetse CN, Thomas BN, Falade CO, Velavan TP, et al. Molecular surveillance of Pfhrp2 and Pfhrp3 genes deletion in Plasmodium falciparum isolates and implications for rapid diagnostic tests in Nigeria. Acta Trop 2019; 196: 121-125. doi: 10.1016/j.actatropica.2019.05.016.

[71] Sathishkumar V, Nirmolia T, Bhattacharyya DR, Patgiri SJ. Genetic polymorphism of Plasmodium falciparum Msp–I, Msp–2 and glurp vaccine candidate genes in pre-artemisinin era clinical isolates from Lakhimpur District in Assam, Northeast India. Access Microbiol 2022; 4(4): 000350. doi: 10.1099/acmi.0.000350.

[72] Yerlikaya S, Owusu EDA, Frimpong A, DeLisle RK, Ding XC. A dual, systematic approach to malaria diagnostic biomarker discovery. Clinic Infect Dis 2021; 74: 40-51. doi: 10.1093/cid/ciab251.

[73] Santamaría AM, Vásquez V, Rigg C, Moreno D, Romero L, Justo C, et al. Plasmodium falciparum genetic diversity in Panamá Based on Glurp, Msp–1 and Msp–2 genes: Implications for malaria elimination in Mesoamerica. Life 2020; 10: 319. doi: 10.3390/life10120319.

[74] Niaré K, Chege T, Rosenkranz M, Mwai K, Saßmannshausen Z, Odera D, et al. Characterization of a novel Plasmodium falciparum merozoite surface antigen and potential vaccine target. Front Immunol 2023; doi: 10.3389/fimmu.2023.1156806.

[75] Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell 2021; 184: 1589-1603. doi: 10.1016/j.cell.2021.02.030.

[76] Ma R, Lian T, Huang R, Renn JP, Petersen JD, Zimmerberg J, et al. Structural basis for placental malaria mediated by Plasmodium falciparum VAR2CSA. Nat Microbiol 2021; 6: 380-391. doi: 10.1038/s41564-020-00858-9.

[77] Beeson JG, Chan JA. A step forward for Plasmodium falciparum malaria transmission-blocking vaccines. Lancet Infect Dis 2023; 23: 1210-1212. doi: 10.1016/s1473-3099(23)00288-8.

[78] Salinas ND, Ma R, Dickey TH, McAleese H, Ouahes T, Long CA, et al. A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle. NPJ Vacc 2023; 8(1): 124. doi: 10.1038/s41541-023-00709-8.

[79] Birkholtz LM, Alano P, Leroy D. Transmission-blocking drugs for malaria elimination. Trends Parasitol 2022; 38: 390-403. doi: 10.1016/j.pt.2022.01.011.

[80] Yihunie W, Kebede B, Tegegne BA, Getachew M, Abebe D, Aschale Y, et al. Systematic review of safety of RTS, S with AS01 and AS02 adjuvant systems using data from randomized controlled trials in infants, children, and adults. Clin Pharma Adv Applic 2023; 15: 21-32. doi: 10.2147/cpaa.s400155.

[81] Sinha A, Kumar S, Dayal D, Yadav V, Pramanik A, Chaubey KK, et al. Elimination of lymphatic filariasis: Where do we stand so far? Asian Pac J Trop Med 2023; 16(9): 385-399.

[82] Baptista B, de Souza O, de Oliveira ABL, de Dos Santos SHA, de Barros JP, de Queiroz LT, et al. B-cell epitope mapping of the Plasmodium falciparum malaria vaccine candidate GMZ2. 6c in a naturally exposed population of the Brazilian Amazon. Vaccines 2023; 11(2): 446. doi: 10.3390/vaccines11020446.

[83] WHO . WHO malaria policy advisory group (MPAG) meeting, October 2022. [Online]. Available from: https://www.who.int/publications/i/item/9789240063303. [20 May 2023].

[84] WHO . Malaria policy advisory committee meeting report (October 2019). [Online]. Available from: https://www.who.int/publications/i/item/9789240063303. [20 May 2023].

[85] Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottilie S, Lukens AK, et al. Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. Science 2018; 362(6419): eaat9446. doi: 10.1126/science.aat9446.

[86] Rao SPS, Manjunatha UH, Mikolajczak S, Ashigbie PG, Diaganaa TT. Drug discovery for parasitic diseases: Powered by technology, enabled by pharmacology, informed by clinical science. Trends Parasitol 2023; 39: 260-271. doi: 10.1016/j.pt.2023.01.010.

[87] Oguike OE, Ugwuishiwu CH, Asogwa CN, Nnadi CO, Obonga WO, Attama AA. Systematic review on the application of machine learning to quantitative structure-activity relationship modeling against Plasmodium falciparum. Molecul Divers 2022; 26: 3447-3462. doi: 10.1007/s11030-022-10380-1.

[88] Panda C, Mahapatra RK. An update on cerebral malaria for therapeutic intervention. Mol Biol Rep 2022; 49: 10579-10591. doi: 10.1007/s11033-022-07625-5.

[89] Martinelli DD. In silico vaccine design: A tutorial in immunoinformatics. Healthc Anal 2022; 2: 100044. doi: 10.1016/j.health.2022.100044.

[90] Atapour A, Vosough P, Jafari S, Sarab GA. A multi-epitope vaccine designed against blood-stage of malaria: An immunoinformatic and structural approach. Sci Rep 2022; 12(1): 11683. doi: 10.1038/s41598-022-15956-3.

[91] Zen LPY, Lai MY, Hamid MHA, Jelip J, Mudin RN, Salleh NHBM, et al. A simple and purification-free nucleic acid extraction method for rapid diagnosis of malaria. Asian Pac J Trop Med 2023; 16(9): 428-430.

[92] Nellimarla S, Kesanakurti P. Next-generation sequencing: A promising tool for vaccines and other biological products. Vaccines 2023; 11: 527. doi: 10.3390/vaccines11030527.

[93] Su X, Stadler RV, Xu F, Wu J. Malaria genomics, vaccine development, and microbiome. Pathogens 2023; 12(8): 1061. doi: 10.3390/pathogens12081061.

[94] Lyimo BM, Popkin-Hall ZR, Giesbrecht DJ, Mandara CI, Madebe RA, Bakari C, et al. Potential opportunities and challenges of deploying next generation sequencing and CRISPR-Cas systems to support diagnostics and surveillance towards malaria control and elimination in Africa. Front Cellu Infect Microbiol 2022; 12: 757844. doi: 10.3389/fcimb.2022.757844.

[95] Kunasol C, Dondorp AM, Batty EM, Nakhonsri V, Sinjanakhom P, Day NPJ, et al. Comparative analysis of targeted next-generation sequencing for Plasmodium falciparum drug resistance markers. Sci Rep 2022; 12: doi: 10.1038/s41598-022-09474-5.

[96] Ragotte RJ, Higgins MK, Draper SJ. The RH5-CyRPA-Ripr complex as a malaria vaccine target. Trends Parasitol 2020; 36: 545-559. doi: 10.1016/j.pt.2020.04.003.

[97] El-Moamly AA, El-Sweify MA. Malaria vaccines: The 60-year journey of hope and final success-lessons learned and future prospects. Trop Med Health 2023; 51(1): 29. doi: 10.1186/s41182-023-00516-w.

[98] Kenangalem E, Poespoprodjo JR, Douglas NM, Burdam FH, Gdeumana K, Chalfein F, et al. Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Med 2019; 16: e1002815. doi: 10.1371/journal.pmed.1002815.

[99] You H, Jones MK, Gordon CA, Arganda AE, Cai P, Al-Wassiti H, et al. The mRNA vaccine technology era and the future control of parasitic infections. Clin Microbiol Rev 2023; 36(1): e0024121. doi: 10.1128/cmr.00241-21.